Smartest Doc
Pfizer voluntarily withdraws sitaxsentan from the market worldwide and halts ongoing clinical trials Full Text
Formulary , 01/27/2011
Based on "a review of emerging safety information from clinical trials and postmarketing reports," Pfizer announced it would be voluntarily withdrawing sitaxsentan (Thelin), the manufacturer's pulmonary artery hypertension (PAH) treatment from the market worldwide. Specifically, 2 cases of idiosyncratic, fatal hepatic failure have been linked to sitaxsentan use.